Literature DB >> 22939575

Juxtaglomerular cell tumor: a morphological, immunohistochemical and genetic study of six cases.

Naoto Kuroda1, Sperga Maris, Federico A Monzon, Puay Hoon Tan, Anjula Thomas, Fredrik B Petersson, Zoran Gatalica, Anatole Ghazalpour, Ryan P Bender, Petr Grossmann, Michal Michal, Marian Svajdler, Zdenka Ovcak, Milan Hora, Ondrej Hes.   

Abstract

Juxtaglomerular cell tumors (JGCTs) are rare tumors characterized by renin synthesis, hyperaldosteronism and hypertension. A curious immunohistochemical overlap between JGCT and gastrointestinal stromal tumor (GIST) including the expression of vimentin, CD34, CD117, α-smooth muscle actin was previously reported, prompting us to further investigate JGCT and its phenotypic and molecular genetic characteristics. Virtual karyotyping showed gain of chromosomes 3, 4, 10, 13, 17 and 18 in one JGCT, and fluorescence in situ hybridization (FISH) study confirmed this multiple gain pattern. Additionally, loss of chromosome 9 was observed in four of six cases analyzed with FISH. A whole genome expression analysis revealed 415 up-regulated (including renin, and CD117) and 325 down-regulated genes between the 2 cases. The study confirmed earlier reports on the gain of chromosomes 4 and 10, and provided further evidence of up-regulation of the genes located on these 2 chromosomes. For the first time our study indicated the importance of the loss of chromosome 9 and loss of expression of several tumor suppressor genes located on this chromosome as possible pathogenetic events important in development of JGCT.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22939575     DOI: 10.1016/j.humpath.2012.04.006

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Juxtaglomerular cell tumor: A case report.

Authors:  Hongyuan Yang; Zufei Wang; Jiansong Ji
Journal:  Oncol Lett       Date:  2015-12-21       Impact factor: 2.967

Review 2.  Renal myopericytoma: a clinicopathologic study of six cases and review of the literature.

Authors:  Jun Li; Ming Zhao; Zhen Chen; Liang Zou; Xiaodong Teng
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Juxtaglomerular cell tumor: Clinical and immunohistochemical features.

Authors:  Fen Wang; Chuan Shi; Yunying Cui; Chunyan Li; Anli Tong
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-03-20       Impact factor: 3.738

4.  The Small Size and Superficial Location Suggest That Laparoscopic Partial Nephrectomy Is the First Choice for the Treatment of Juxtaglomerular Cell Tumors.

Authors:  Zixing Ye; Hua Fan; Anli Tong; Yu Xiao; Yushi Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-30       Impact factor: 5.555

5.  Magnetic Resonance Imaging Features of a Juxtaglomerular Cell Tumor.

Authors:  Suhai Kang; Aitao Guo; Haiyi Wang; Lu Ma; Zongyu Xie; Jinglong Li; Xinyuan Tonge; Huiyi Ye
Journal:  J Clin Imaging Sci       Date:  2015-12-31

6.  Case Report of Atypical Juxtaglomerular Cell Tumor.

Authors:  Satoru Munakata; Eisuke Tomiyama; Hitoshi Takayama
Journal:  Case Rep Pathol       Date:  2018-10-24

7.  Spindle Cell Hemangioma and Atypically Localized Juxtaglomerular Cell Tumor in a Patient with Hereditary BRIP1 Mutation: A Case Report.

Authors:  Jan Papez; Jiri Starha; Pavel Zerhau; Denisa Pavlovska; Marta Jezova; Tomas Jurencak; Katerina Slaba; Martin Sterba; Arpad Kerekes; Tomas Merta; Terezia Haluskova; Hana Palova; Ondrej Slaby; Jaroslav Sterba; Petr Jabandziev
Journal:  Genes (Basel)       Date:  2021-02-03       Impact factor: 4.096

8.  Malignant juxtaglomerular cell tumor.

Authors:  Daniel Geisler; Fawaz Almutairi; Ivy John; Gabriela Quiroga-Garza; Michelle Yu; Raja Seethala; Sheldon Bastacky
Journal:  Urol Case Rep       Date:  2022-07-31

9.  Reninoma: an uncommon cause of Renin-mediated hypertension.

Authors:  Peter Trnka; Luisa Orellana; Mark Walsh; Louis Pool; Peter Borzi
Journal:  Front Pediatr       Date:  2014-08-15       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.